Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of GSK 692342 TB Vaccine in HIV-positive Adults
NCT01262976Phase 2Completed
- Sponsor
- GSK
- Start
- Jan 2011
- Primary completion
- Jul 2012
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of M72 + AS01E in Tuberculosis (TB), sponsored by GSK. Started Jan 2011; status: completed.
02
Drugs
M72 + AS01E
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT01262976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01262976.